Abstract 240P
Background
This study aimed to investigate the role of the serpin peptidase inhibitor, clade E, member 2 (SERPINE2), in patients with oral squamous cell carcinoma (OSCC).
Methods
We investigated SERPINE2 mRNA expression in cases of squamous cell carcinoma from online databases, explored the relationship between SERPINE2 and clinicopathological characteristics and prognosis in OSCC patients, and determined the potential of SERPINE2 to affect OSCC proliferation, migration and invasion capability in vitro.
Results
The expressions of SERPINE2 were higher in tumor tissues than that in normal tissues in TNMplot. High mRNA expression of SERPINE2 was significantly correlated with poor overall 5-year survival in KmPlot. High SERPINE2 immunoexpression was significantly correlated with adverse pathologic parameters. High SERPINE2 immunoexpression was significantly associated with worse overall survival. SERPINE2 promotes cell proliferation, cell migration, and invasion ability in OSCC cell lines. Table: 240P
Relationships between the immunoscore of SERPINE2 and clinicopathological parameters in 122 patients
Parameters | No. | Mean ± SEM | Median | p | |
Agea | |||||
≤ 54 | 73 | 147.47 ± 7.77 | 160 | 0.132 | |
> 54 | 49 | 163.83 ± 8.86 | 165 | ||
Gendera | |||||
Male | 107 | 152.59 ± 6.45 | 160 | 0.561 | |
Female | 15 | 164.33 ± 13.21 | 160 | ||
Tumor siteb | |||||
Buccal | 77 | 152.08 ± 7.29 | 160 | 0.700 | |
Retromolar | 24 | 148.96 ± 13.50 | 165 | ||
Tongue | 7 | 170.36 ± 25.33 | 170 | ||
Others | 14 | 165.36 ± 19.25 | 171 | ||
Histological gradeb | |||||
Well | 45 | 149.00 ± 8.18 | 165 | 0.720 | |
Moderate | 71 | 156.13 ± 8.35 | 160 | ||
Poor | 6 | 167.08 ± 30.81 | 183 | ||
Stagea | |||||
I–II | 66 | 133.60 ± 7.41 | 153 | <0.001* | |
III–IV | 56 | 178.13 ± 8.34 | 184 | ||
Tumor statusa | |||||
T1–2 | 78 | 139.20 ± 7.18 | 160 | <0.001* | |
T3–4 | 44 | 180.34 ± 8.98 | 186 | ||
Nodal metastasisa | |||||
Absent | 91 | 145.36 ± 6.39 | 160 | 0.011* | |
Present | 31 | 179.52 ± 12.64 | 180 | ||
Distant metastasisa | |||||
Absent | 107 | 148.69 ± 6.36 | 160 | 0.010* | |
Present | 15 | 192.17 ± 11.12 | 188 |
ap-value by Mann–Whitney U testbp-value by Kruskal–Wallis test. *Significance at p < 0.05
Conclusions
Our results suggest that SERPINE2 may serve as a prognostic biomarker, associated with the tumorigenesis and aggressiveness of OSCC, and a potential therapeutic target in oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This research was supported by a grant from Kaohsiung Veterans General Hospital (grant number VGHKS109-074) in Taiwan, ROC.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03